MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
企業コードMNKD
会社名MannKind Corp
上場日Jul 28, 2004
最高経営責任者「CEO」Dr. Michael E. Castagna, Pharm.D.
従業員数407
証券種類Ordinary Share
決算期末Jul 28
本社所在地1 Casper Street
都市DANBURY
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号06810
電話番号18186615000
ウェブサイトhttps://mannkindcorp.com/
企業コードMNKD
上場日Jul 28, 2004
最高経営責任者「CEO」Dr. Michael E. Castagna, Pharm.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし